IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in IN8BIO, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +2 vs. Q1 2026
- Shares held
- 3.79M
- +37.0K (+1.0%) vs. Q1 2026
- Total value
- $5.35M
- −$209.3K (−3.8%) vs. Q1 2026
- New holders
- 3
- 5 more added
- Sold out
- 1
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 944,319 | $1.33M | 0.00% | 00.0% | Unchanged |
| Franklin Resources Inc | 914,531 | $1.29M | 0.00% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 724,637 | $1.02M | 0.09% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 695,287 | $980.4K | 0.75% | +31,875+4.8% | Added |
| Vanguard Capital Management LLC | 88,865 | $126.5K | 0.00% | 00.0% | Unchanged |
| BIOS Capital Management, LP | 80,957 | $114.1K | 0.27% | −86,848−51.8% | Reduced |
| Geode Capital Management, LLC | 72,550 | $102.3K | 0.00% | −13,689−15.9% | Reduced |
| Citadel Advisors LLC | 63,055 | $88.9K | 0.00% | +63,055 | New |
| Oppenheimer & Co Inc | 63,042 | $88.9K | 0.00% | +39,009+162.3% | Added |
| Vanguard Fiduciary Trust Co | 43,570 | $62.0K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 33,295 | $46.9K | 0.00% | 00.0% | Unchanged |
| Texas Capital Bank Wealth Management Services Inc | 24,406 | $34.4K | 0.00% | +656+2.8% | Added |
| Northern Trust Corp | 21,734 | $30.6K | 0.00% | +1,294+6.3% | Added |
| Renaissance Technologies LLC | 12,100 | $17.1K | 0.00% | +12,100 | New |
| Tower Research Capital LLC (TRC) | 3,738 | $5.27K | 0.00% | +2,473+195.5% | Added |
| Northwestern Mutual Wealth Management Co | 2,785 | $3.93K | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 768 | $1.04K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 84 | $118 | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 83 | $117 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 28 | $39 | 0.00% | +28 | New |
| UBS Group AG | 1 | $1 | 0.00% | −479−99.8% | Reduced |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,433−100.0% | Sold out |